Ann Pediatr Endocrinol Metab.  2024 Feb;29(1):12-18. 10.6065/apem.2346114.057.

Pediatric and adult osteoporosis: a contrasting mirror

• Ferjani HL
• Cherif I
• Nessib DB
• Kaffel D
• Maatallah K
• Hamdi W

• KMID: 2553013
• DOI: http://doi.org/10.6065/apem.2346114.057

Abstract

Pediatric osteoporosis (PO) is a condition that is currently gaining recognition. Due to the lack of official definitions over the past few decades, the exact incidence of PO is unknown. The research does not provide a specific prevalence of PO in different world regions. However, this is expected to change with the latest 2019 guidelines proposed by the International Society of Clinical Densitometry. Although adult osteoporosis (AO) has been postulated a pediatric disease because its manifestation in adulthood is a result of the bone mass acquired during childhood, differences between PO and AO should be acknowledged. AO is defined as low bone density; however, PO is diagnosed based on existing evidence of bone fragility (vertebral fractures, pathological fractures). This is particularly relevant because unlike in adults, evidence is lacking regarding the association between low bone density and fracture risk in children. The enhanced capacity of pediatric bone for reshaping and remodeling after fracture is another difference between the two entities. This contrast has therapeutic implications because medication-free bone reconstitution is possible under certain conditions; thus, background therapy is not always recommended. In this narrative review, differences between PO and AO in definition, assessment, and medical approach were investigated.

Keyword

Osteoporosis; Bone fragility; Child; Adults; Dual-energy x-ray absorptiometry; Bisphosphonates

Reference

References

1. Cloutier MD, Hayles AB, Riggs BL, Jowsey J, Bickel WH. Juvenile osteoporisis: report of a case including a description of some metabolic and microradiographic studies. Pediatrics. 1967; 40:649–55.

2. Writing Group for the ISCD Position Development Conference. Diagnosis of osteoporosis in men, premenopausal women, and children. J Clin Densitom. 2004; 7:17–26.

3. Shuhart CR, Yeap SS, Anderson PA, Jankowski LG, Lewiecki EM, Morse LR, et al. Executive summary of the 2019 ISCD position development conference on monitoring treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics. J Clin Densitom. 2019; 22:453–71.

4. Bishop N, Arundel P, Clark E, Dimitri P, Farr J, Jones G, et al. Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 Pediatric Official Positions. J Clin Densitom. 2014; 17:275–80.

5. Baim S, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Lewiecki EM, et al. Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom. 2008; 11:75–91.

6. Vokes T, Bachman D, Baim S, Binkley N, Broy S, Ferrar L, et al. Vertebral fracture assessment: the 2005 ISCD Official Positions. J Clin Densitom. 2006; 9:37–46.

7. Writing Group for the ISCD Position Development Conference. Position statement: executive summary. The Writing Group for the International Society for Clinical Densitometry (ISCD) Position Development Conference. J Clin Densitom. 2004; 7:7–12.

8. Forestier-Zhang L, Bishop N. Bone strength in children: understanding basic bone biomechanics. Arch Dis Child Educ Pract Ed. 2016; 101:2–7.

9. Chesnut CH 3rd. Is osteoporosis a pediatric disease? Peak bone mass attainment in the adolescent female. Public Health Rep. 1989; 104 Suppl(Suppl):50–4.

10. Chan CY, Mohamed N, Ima-Nirwana S, Chin KY. A review of knowledge, belief and practice regarding osteoporosis among adolescents and young adults. Int J Environ Res Public Health. 2018; 15:1727.

11. Fleming R, Patrick K. Osteoporosis prevention: pediatricians’ knowledge, attitudes, and counseling practices. Prev Med. 2002; 34:411–21.

12. WHO Scientific Group on the Prevention and Management of Osteoporosis (2000 : Geneva S. Prevention and management of osteoporosis : report of a WHO scientific group [Internet]. Geneva (Switzerland): World Health Organization;2003. [cited 2023 Aug 13]. Available from: https://apps.who.int/iris/handle/10665/42841.

13. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007; 18:1033–46.

14. Ma J, McMillan HJ, Karagüzel G, Goodin C, Wasson J, Matzinger MA, et al. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy. Osteoporos Int. 2017; 28:597–608.

15. Clark EM. The epidemiology of fractures in otherwise healthy children. Curr Osteoporos Rep. 2014; 12:272–8.

16. Simpson DE, Dontu VS, Stephens SE, Archbold LJ, Lowe V, O’Doherty MJ, et al. Large variations occur in bone density measurements of children when using different software. Nucl Med Commun. 2005; 26:483–7.

17. Cromer BA, Binkovitz L, Ziegler J, Harvey R, Debanne SM. Reference values for bone mineral density in 12- to 18-yearold girls categorized by weight, race, and age. Pediatr Radiol. 2004; 34:787–92.

18. Arabi A, Nabulsi M, Maalouf J, Choucair M, Khalifé H, Vieth R, et al. Bone mineral density by age, gender, pubertal stages, and socioeconomic status in healthy Lebanese children and adolescents. Bone. 2004; 35:1169–79.

19. Crabtree NJ, Shaw NJ, Bishop NJ, Adams JE, Mughal MZ, Arundel P, et al. Amalgamated reference data for sizeadjusted bone densitometry measurements in 3598 children and young adults-the ALPHABET study. J Bone Miner Res. 2017; 32:172–80.

20. Lopez-Gonzalez D, Wells JC, Cortina-Borja M, Fewtrell M, Partida-Gaytán A, Clark P. Reference values for bone mineral density in healthy Mexican children and adolescents. Bone. 2021; 142:115734.

21. Kalkwarf HJ, Shepherd JA, Fan B, Sahay RD, Ittenbach RF, Kelly A, et al. Reference ranges for bone mineral content and density by dual energy x-ray absorptiometry for young children. J Clin Endocrinol Metab. 2022; 107:e3887–900.

22. LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, et al. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022; 33:2049–102.

23. El Maghraoui A, Roux C. DXA scanning in clinical practice. QJM. 2008; 101:605–17.

24. Scholz R, Borte G, von Salis-Soglio G, Heyde CE. Fehlermöglichkeiten und Interpretationsprobleme der Osteodensitometrie [Pitfalls and difficulties in interpretation of bone densitometry]. Orthopade. 2010; 39:361–70.

25. Krueger D, Shives E, Siglinsky E, Libber J, Buehring B, Hansen KE, et al. DXA errors are common and reduced by use of a reporting template. J Clin Densitom. 2019; 22:115–24.

26. Leonard MB. Assessment of bone health in children and adolescents with cancer: promises and pitfalls of current techniques. Med Pediatr Oncol. 2003; 41:198–207.

27. El-Gazzar A, Högler W. Mechanisms of bone fragility: from osteogenesis imperfecta to secondary osteoporosis. Int J Mol Sci. 2021; 22:625.

28. Ward LM. Part I: which child with a chronic disease needs bone health monitoring? Curr Osteoporos Rep. 2021; 19:278–88.

29. Galindo-Zavala R, Bou-Torrent R, Magallares-López B, Mir-Perelló C, Palmou-Fontana N, Sevilla-Pérez B, et al. Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children. Pediatr Rheumatol Online J. 2020; 18:20.

30. Beck JJ, Mahan ST, Nowicki P, Schreiber VM, Minkowitz B. What is new in pediatric bone health. J Pediatr Orthop. 2021; 41:e594. –9.

31. ACR previews updated guidelines for prevention, treatment of glucocorticoid-induced osteoporosis [Internet]. Atlanta (GA): American College of Rheumatology; 2022 [cited 2022 Dec 28]. Available from: https://www.rheumatologynetwork.com/view/acr-previews-updatedguidelines-for-prevention-treatment-of-glucocorticoidinduced-osteoporosis.

32. Bachrach LK, Gordon CM, Section on endocrinology. Bone densitometry in children and adolescents. Pediatrics. 2016; 138:e20162398.

33. Tan VPS, Macdonald HM, Kim S, Nettlefold L, Gabel L, Ashe MC, et al. Influence of physical activity on bone strength in children and adolescents: a systematic review and narrative synthesis. J Bone Miner Res. 2014; 29:2161–81.

34. Janz KF, Letuchy EM, Burns TL, Eichenberger Gilmore JM, Torner JC, Levy SM. Objectively measured physical activity trajectories predict adolescent bone strength: Iowa Bone Development Study. Br J Sports Med. 2014; 48:1032–6.

35. Economos CD, Hennessy E, Chui K, Dwyer J, Marcotte L, Must A, et al. Beat osteoporosis - nourish and exercise skeletons (BONES): a group randomized controlled trial in children. BMC Pediatr. 2020; 20:83.

36. Kanis JA, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019; 30:3–44.

37. Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2014; (7):CD005088.

38. Ward LM. Glucocorticoid-induced osteoporosis: why kids are different. Front Endocrinol. 2020; 11:576.

39. Tadrous M, Wong L, Mamdani MM, Juurlink DN, Krahn MD, Lévesque LE, et al. Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporos Int. 2014; 25:1225–35.

40. Mitsuhata C, Kozai K. Management of bisphosphonate preparation-treated children in the field of pediatric dentistry. Jpn Dent Sci Rev. 2022; 58:155–61.

41. Simm PJ, Biggin A, Zacharin MR, Rodda CP, Tham E, Siafarikas A, et al. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J Paediatr Child Health. 2018; 54:223–33.

42. Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology. 1999; 60:68–73.

43. Sokal A, Elefant E, Leturcq T, Beghin D, Mariette X, Seror R. Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study. Osteoporos Int. 2019; 30:221–9.

44. Green SB, Pappas AL. Effects of maternal bisphosphonate use on fetal and neonatal outcomes. Am J Health-Syst Pharm. 2014; 71:2029–36.

45. Levy S, Fayez I, Taguchi N, Han JY, Aiello J, Matsui D, et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone. 2009; 44:428–30.

46. Stathopoulos IP, Liakou CG, Katsalira A, Trovas G, Lyritis GG, Papaioannou NA, et al. The use of bisphosphonates in women prior to or during pregnancy and lactation. Horm Athens Greece. 2011; 10:280–91.

47. Losada I, Sartori L, Di Gianantonio E, Zen M, Clementi M, Doria A. Bisphosphonates in patients with autoimmune rheumatic diseases: can they be used in women of childbearing age? Autoimmun Rev. 2010; 9:547–52.

48. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017; 5:513–23.

49. Boyce AM. Denosumab: an emerging therapy in pediatric bone disorders. Curr Osteoporos Rep. 2017; 15:283–92.

50. Sakka SD, Cheung MS. Management of primary and secondary osteoporosis in children. Ther Adv Musculoskelet Dis. 2020; 12:1759720X20969262.

51. Ward LM, Rauch F. Anabolic therapy for the treatment of osteoporosis in childhood. Curr Osteoporos Rep. 2018; 16:269–76.